• Repare Therapeutics, a Montreal and Boston - based
developer of oncology drugs, raised $ 68 million in Series A funding.
• Cullinan Oncology,
a developer of oncology therapeutics, raised $ 150 million in Series A funding.
Not exact matches
• Surface
Oncology, a Cambridge, Mass. - based cancer antibody
developer, filed for an IPO
of up to $ 75 million.
«Dr. Hambleton is an accomplished industry executive and a leading
oncology drug
developer, and we welcome her to the leadership team at IDEAYA,» said Yujiro S. Hata, chief executive officer
of IDEAYA.
Drug
developer Loxo
Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one
of its experimental cancer drugs, across tumor types.
April 10 Drug
developer Loxo
Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one
of its experimental cancer drugs, across tumor types.
This meeting provides a nexus for diagnostic
developers in academia and industry as well as end - users in the pharmaceutical and healthcare sector to gain a comprehensive picture
of molecular diagnostics in prenatal,
oncology, infectious disease, point -
of - care, and liquid biopsy.